 WATERTOWN, Mass., Oct. 29, 2020 GLOBE NEWSWIRE -- Selecta Biosciences, Inc. NASDAQ: SELB, a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTORTM, today announced that it plans to host a conference call on November 5, 2020 at 8:30 a.m. ET to discuss its financial results for the third quarter and recent operational highlights. 